Illumina (NASDAQ:ILMN) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Illumina (NASDAQ:ILMN) announced its earnings results on Thursday. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08, FiscalAI reports. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the prior year, the business earned $1.19 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. Illumina updated its FY 2026 guidance to 5.300-5.400 EPS.

Here are the key takeaways from Illumina’s conference call:

• Q2 exceeded expectations: Revenue rose 9.5% year over year to $1.16 billion, organic rest-of-world growth was 8.1%, and non-GAAP EPS increased 10% to $1.31. Operating margin also came in above guidance despite higher freight and memory costs.
• Clinical demand remains the primary growth engine, with clinical sequencing consumables up 15% outside China and U.S.-Canada growth above 20%. Illumina placed more than 95 NovaSeq X instruments in the quarter, expanding the installed base and supporting future consumables pull-through.
• Management raised full-year 2026 guidance to rest-of-world organic revenue growth above 5%, reported revenue of $4.60 billion-$4.64 billion, and non-GAAP EPS of $5.30-$5.40. The company continues to target high-single-digit revenue growth in 2027.
• Research and academic customers remain cautious amid funding uncertainty; research and applied consumables declined 7% in the quarter, and Illumina still expects mid- to high-single-digit declines in this market for 2026.
• Illumina is expanding beyond core sequencing through spatial biology, proteomics, and BioInsite. The Billion Cell Atlas has delivered more than 300 million cells, generated initial revenue, and added three partners after quarter-end, bringing the total to six, although management characterized the opportunity as still early.

Illumina Stock Performance

Illumina stock traded up $10.27 during trading hours on Thursday, hitting $205.09. The stock had a trading volume of 2,763,533 shares, compared to its average volume of 1,646,504. Illumina has a fifty-two week low of $88.00 and a fifty-two week high of $205.47. The company has a market cap of $31.03 billion, a PE ratio of 37.29, a price-to-earnings-growth ratio of 2.88 and a beta of 1.47. The company has a 50-day moving average of $175.49 and a two-hundred day moving average of $146.83. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ILMN shares. Guggenheim raised their target price on shares of Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Thursday, May 14th. Sanford C. Bernstein began coverage on Illumina in a research report on Friday, June 26th. They set a “market perform” rating and a $185.00 price objective for the company. Canaccord Genuity Group lifted their price target on Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Finally, Piper Sandler increased their price objective on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 1st. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $156.88.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 beat expectations: Revenue rose approximately 9.4% year over year to $1.16 billion, exceeding the $1.13 billion consensus estimate. Non-GAAP diluted EPS was $1.31, above expectations of about $1.23, while GAAP diluted EPS reached $1.35. Illumina Fiscal Q2 Earnings, Revenue Rise; 2026 Guidance Revised
• Positive Sentiment: Improved operating performance: Gross profit increased 10.8% to $770 million, and operating profit rose 14.5% to $245 million. Illumina reported a 21.1% GAAP operating margin and a 22.5% non-GAAP operating margin, supporting the case for expanding profitability. Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
• Positive Sentiment: FY 2026 outlook was favorable: Adjusted EPS guidance was set at $5.30-$5.40, above the roughly $5.23 analyst consensus. Revenue guidance of approximately $4.6 billion, with a midpoint near $4.62 billion, was also modestly ahead of expectations. Illumina Surprises With Q2 Sales and Outlook
• Positive Sentiment: Strategic validation: Eli Lilly joined Illumina’s Billion Cell Atlas alliance as a foundational participant, potentially strengthening Illumina’s position in genomic data and AI-driven drug discovery. Eli Lilly Joins Illumina’s Billion Cell Atlas
• Neutral Sentiment: Reported insider trading data showed substantially more selling than buying over the past six months, although the activity was not directly tied to the quarterly announcement and may have limited near-term relevance.

Insiders Place Their Bets

In related news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the sale, the chief accounting officer directly owned 14,946 shares in the company, valued at $2,243,394.60. This trade represents a 9.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,003,769 shares of company stock valued at $155,710,908 in the last ninety days. 2.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Illumina

A number of hedge funds have recently modified their holdings of the stock. Quarry LP bought a new stake in Illumina in the third quarter valued at $32,000. Brown Brothers Harriman & Co. lifted its holdings in shares of Illumina by 975.6% during the fourth quarter. Brown Brothers Harriman & Co. now owns 441 shares of the life sciences company’s stock valued at $58,000 after acquiring an additional 400 shares during the period. Itau Unibanco Holding S.A. boosted its stake in shares of Illumina by 93.1% in the 4th quarter. Itau Unibanco Holding S.A. now owns 556 shares of the life sciences company’s stock valued at $73,000 after purchasing an additional 268 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of Illumina in the 3rd quarter valued at $102,000. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Illumina by 16.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,329 shares of the life sciences company’s stock worth $176,000 after purchasing an additional 186 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.